Aisar Biotechnology provides research and clinical treatment-level human-derived cell products and technical services for basic medicine, translational medicine, and new drug screening. Since its establishment, the company has been committed to product development and technology promotion with iPSCs as the core. At present, Aisar has independently developed a series of induced pluripotent stem cell products: IxCellTM-iPS-D1 cell line, IxCellTM-Neural Stem Cells, IxCellTM-Cardiomycytes, IxCellTM-Hepatocytes.